CL2007002876A1 - Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de - Google Patents

Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de

Info

Publication number
CL2007002876A1
CL2007002876A1 CL200702876A CL2007002876A CL2007002876A1 CL 2007002876 A1 CL2007002876 A1 CL 2007002876A1 CL 200702876 A CL200702876 A CL 200702876A CL 2007002876 A CL2007002876 A CL 2007002876A CL 2007002876 A1 CL2007002876 A1 CL 2007002876A1
Authority
CL
Chile
Prior art keywords
compound
peguiled
mammer
osea
treatment
Prior art date
Application number
CL200702876A
Other languages
English (en)
Inventor
Lea Brown-Augsburger Patricia
Original Assignee
Eli Lilly And Company Soc Orga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company Soc Orga filed Critical Eli Lilly And Company Soc Orga
Publication of CL2007002876A1 publication Critical patent/CL2007002876A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/635Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL200702876A 2006-10-13 2007-10-05 Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de CL2007002876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82938306P 2006-10-13 2006-10-13

Publications (1)

Publication Number Publication Date
CL2007002876A1 true CL2007002876A1 (es) 2008-06-06

Family

ID=38974655

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200702876A CL2007002876A1 (es) 2006-10-13 2007-10-05 Compuesto peptidico peguilado; compuesto intermediario; composicion que comprende dicho compuesto; metodo de induccion de formacion osea en un mamifero que comprende tratar con dicho compuesto peguilado; uso de dicho compuesto para el tratamiento de

Country Status (12)

Country Link
AR (1) AR063251A1 (es)
CL (1) CL2007002876A1 (es)
CO (1) CO6190624A2 (es)
CR (1) CR10681A (es)
CY (1) CY1110701T1 (es)
DE (1) DE602007006839D1 (es)
ES (1) ES2343917T3 (es)
MA (1) MA30873B1 (es)
PE (1) PE20080981A1 (es)
PT (1) PT2084183E (es)
TW (1) TW200817439A (es)
ZA (1) ZA200901853B (es)

Also Published As

Publication number Publication date
ZA200901853B (en) 2010-05-26
CR10681A (es) 2009-07-13
AR063251A1 (es) 2009-01-14
ES2343917T3 (es) 2010-08-12
CO6190624A2 (es) 2010-08-19
MA30873B1 (fr) 2009-11-02
CY1110701T1 (el) 2015-06-10
PT2084183E (pt) 2010-07-16
TW200817439A (en) 2008-04-16
PE20080981A1 (es) 2008-07-19
DE602007006839D1 (de) 2010-07-08

Similar Documents

Publication Publication Date Title
EP2056753A4 (en) METHOD AND DEVICE FOR TREATING DRIVE DYSFUNCTION
FI20065147A (fi) Järjestelmä ja menetelmä harjoittelun ohjaamiseksi
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
CL2008000822A1 (es) Metodo para el tratamiento de la obesidad usando un inhibidor sglt2.
EP1989587A4 (en) LIGHT-EMITTING COMPONENT AND METHOD FOR CONTROLLING IT
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
DK1829592T3 (da) Linearmotordrevet kørende forlystelse samt fremgangsmåde
SI2520295T1 (sl) Postopki za preprečevanje in zdravljenje mukozitisa
DE602006010196D1 (de) Zementzusammensetzungen mit umweltverträglichen entschäumern und verwendungsverfahren
BRPI0818544A2 (pt) Processo para tratamento de uma combinação contendo organossilano, composição e uso de uma resina orgânica.
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
ATE465229T1 (de) Textilbehandlungsverfahren und zusammensetzung
BRPI0810738A2 (pt) aparelho e método para tratar materiais com composições.
BRPI0909885A2 (pt) composição decorativa e método para sua utilização
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
TWI372576B (en) Organic light-emitting device and method for forming the same
EP2037941A4 (en) COBALAMINE COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF MUCOSITIS
BRPI0819931A2 (pt) Composições tópicas que compreendem aminoácidos não-proteogênicos e métodos de tratamento de pele
EP2086320A4 (en) COMPOSITIONS AND METHODS FOR TREATING MEDUSES
CL2013002903A1 (es) Composicion que comprende azadiractina; metodo para el tratamiento anti-macroincrustacion de al menos un polimeros; y su uso.
CL2008000093A1 (es) Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria.
ZA200805870B (en) One-way valve and apparatus and method of using the valve
CR10853A (es) Metodo para el tratamiento de fisuras en estructuras de concreto